

Activity Title: The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies

Estimated Time to Complete Activity: 60 minutes

Credit Available

1.0 *AMA PRA Category 1 Credit(s)*TM (Physician)

1.0 CNE Contact Hours (Nurses)

0.5 Contact hours of pharmacotherapy credit for Advance Practice Registered Nurses

Target Audience

The audience for this educational initiative is physicians and advanced practice clinicians who care for people with rare blood disorders.

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and CMEology.



Supported by an independent educational grant from Sanofi.

Program Overview

Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it is essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura; developments in the diagnosis and treatment of cold agglutinin disease; and the challenges of achieving enduring remission in patients with immune thrombocytopenia.

Learning Objectives

On completion of this activity the learner will be better able to:

- Describe the recent ISTH evidence-based recommendations for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura (aTTP)
- Explain the diagnosis and management of cold agglutinin disease (CAD) to control anemia and reduce fatigue
- Summarize the mechanism of action, efficacy and safety, and potential place in therapy for emerging immune thrombocytopenia (ITP) therapies

Learning Goal

The goal of this activity is to enhance the knowledge and competence that clinicians need to diagnose and treat immune-mediated rare blood disorders, thereby improving patient outcomes.

Faculty

Moderator

David J. Kuter, MD, DPhil
Professor of Medicine
Harvard Medical School
Hematology Program Director
Massachusetts General Hospital
Boston, Massachusetts

Faculty (3 total)

Spero R. Cataland, MD
Professor of Internal Medicine
Division of Hematology, Benign Hematology Section Head
Wexner Medical Center at The Ohio State University
Columbus, Ohio

Catherine M. Broome, MD
Professor of Medicine
Division of Hematology Oncology
MedStar Georgetown University
Washington, DC

Cindy Neunert, MD, MSCS
Section Head, Pediatric Hematology
Associate Professor, Pediatrics
Columbia University Irving Medical Center
New York, New York

Joint Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and CMEology. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

PACE designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure of Conflict of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty	Conflicts of Interest
Dr. Kuter	<i>Researcher:</i> Alnylam, BioCryst, Novartis, Rigel, Sanofi (Principia), Takeda (Bioverativ), UC <i>Consultant, Advisor, Speaker:</i> AIRx, Alexion (Syntimmune), Alnylam, Alpine, Amgen, Argenx, BioCryst, Bristol Myers Squibb (BMS), Caremark, Cellularity, Cellphire, Chugai, CRICO, Daiichi Sankyo, Dianthus, Electra Therapeutics, Fuji, Hemopure, Hengrui, Immunovant, Incyte, Inmagenebio, Kezar, Kyowa-Kirin, Merck Sharp & Dohme, Momenta, Novartis, Nuvig, Pfizer, Platelet Biogenesis, Protagonist, Rigel, Sanofi (Bioveratif), Sanofi (Principia), Sanofi (Genzyme), Sobi (Dova), Takeda, UCB, Up-To-Date, Zafgen <i>Individual publicly traded stocks or stock options:</i> Rubius
Dr. Cataland	<i>Consultant, Advisor, Speaker:</i> Sanofi, Takeda
Dr. Broome	<i>Researcher:</i> Alpine, Novartis, Star <i>Consultant, Advisor, Speaker:</i> Alexion, Argenx, Sanofi
Dr. Neunert	<i>Researcher:</i> Novartis <i>Consultant, Advisor, Speaker:</i> Dova, Janssen, Novartis, Sanofi

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturers' product information, and comparison with recommendations of other authorities.

Instructions

Participation in this self-study activity should be completed in approximately 60 minutes. To successfully complete this activity and receive CE credit, learners must follow these steps:

1. Review the objectives and disclosures
2. Study the educational content
3. Successfully complete activity post-test(s)
4. Complete the activity evaluation

In order to receive CME/CE credits, participants must complete the post-assessment and program evaluation. Participants must also score at least 70% on the post-assessment. Certificates will be distributed online at the conclusion of the activity.

Computer system hardware/software requirements

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.

For additional information about the accreditation of this activity, please visit <https://partnersed.com>.